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Objective. Graves’ disease is the most common cause of hyperthyroidism in the pediatric population. Antithyroid medications
used in children and adults include propylthiouracil (PTU) and methimazole (MMI). At our center we have routinely used MMI
for Graves’ disease therapy. Our goals are to provide insights into adverse events that can be associated with MMI use. Methods.
We reviewed the adverse events associated with MMI use in our last one hundred consecutive pediatric patients treated with this
medication. Results. The range in the patient age was 3.5 to 18 years. The patients were treated with an average daily dose of
MMI of 0.3 ± 0.2mg/kg/day. Adverse events attributed to the use of the medication were seen in 19 patients at 17 ± 7w e e k so f
therapy .Themostc ommonsideeﬀectsincludedpruritusandhives,whichwereseenin8patients.Threepatientsdevelopeddiﬀuse
arthralgia and joint pain. Two patients developed neutropenia. Three patients developed Stevens-Johnson syndrome, requiring
hospitalization in 1 child. Cholestatic jaundice was observed in 1 patient. No speciﬁc risk-factors for the development of adverse
events were identiﬁed. Conclusions. MMI use in children is associated with a low but real risk of minor and major side eﬀects.
1.Introduction
Graves’ disease is the most common cause of hyperthyroi-
dism in the pediatric population [1, 2]. Treatment options
for Graves’ disease include antithyroid medications, radio-
active iodine, and surgery [1, 2]. Antithyroid medications
used in children and adults include propylthiouracil (PTU)
and methimazole (MMI), and carbimazole, which is
metabolized to MMI, and is available in Europe but not the
United States [3].
Recently, a signiﬁcant safety concern related to hepato-
toxicityriskassociatedwithPTUuseinchildrenwasbrought
toattention[4,5].ItisthusnowrecommendedthatPTUnot
be used in children, except in special circumstances [4, 5],
and MMI should be used for antithyroid drug therapy in
children.
To date, the majority of publications related to medical
therapy for Graves’ disease have focused on children treated
with PTU [6–14]. The use of MMI in children has been
described in far fewer reports [15]. The description of the
natureofadverseeventsthatareassociatedwithmethimazole
use in the pediatric population is modest, as well.
At our center, we have routinely used MMI for Graves’
disease therapy for many years. To provide insights into
adverse events that can be associated with MMI use, we
reviewed the adverse events associated with MMI use in our
last one hundred consecutive pediatric patients treated with
this medication.
2.Methods andMaterials
This review of treatment practice outcomes was conducted
withtheapprovaloftheYaleUniversityHumanInvestigation
Committee. All adverse events were reported to the United
States Food and Drug Administration via the MedWatch
program. Patients with the diagnosis of Graves’ disease were
identiﬁed from ICD-9 coding (242.0 or 242.9).
The diagnosis of Graves’ disease was made if there were
elevated total and/or free thyroxine [T4] and/or triiodothy-
ronine [T3] concentrations, subnormal thyrotropin levels,
and evidence of thyroid autoimmunity not thought to be
consistent with Hashitoxicosis. The presence of goiter and
ophthalmopathy supported the diagnosis of Graves’ disease;
however eye disease was present in only 60% of the patients.2 International Journal of Pediatric Endocrinology
Table 1: Adverse events associated with methimazole.
Age at diagnosis Gender MMI dose at time Duration of therapy Reaction
of AE (mg/day) at time of AE
3 5/12 M 10 12 weeks Mild liver injury
4 M 10 32 weeks Myalgias/joint pain/facial urticaria
4 4/12 F 10 2 weeks Pruritis and hives
4 3/4 F 30 2 weeks Stevens-Johnson syndrome
51 / 1 2 F 7 . 5 3w e e k s D i ﬀuse urticaria
7 10/12 F 15 4 weeks Arthralgia
8 2/12 F 10 2 weeks Rash and joint pain
84 / 1 2 F 1 0 3w e e k s U r t i c a r i a
85 / 1 2 M 2 0 9w e e k s A r t h r a l g i a
8 10/12∗ M 10 18 months Neutropenia (ANCA+)
8 10/12∗ M 10 18 months Neutropenia (ANCA−)
10 7/12 M 40 4 weeks Myalgias
11 1/2 F 20 4 weeks Lymphopenia and eosinophilia
12 5/12 F 20 12 weeks Myalgias
12 6/12 F 30 12 weeks Stevens-Johnson syndrome (hospitalization)
14 2/12 F 30 4 weeks Stevens-Johnson, syndrome
15 4/12 F 30 2 weeks Rash
16 11/12 F 20 4 weeks Rash on arms and face
17 6/12 F 30 3 weeks Pruritic rash
∗identical twins
In situations where there was a question of the diagnosis, a
123Iuptakeandscanwasperformed.Patientswerediagnosed
with Graves’ disease in this setting only if the 123Iu p t a k ew a s
elevated.
The medical records of the last 100 consecutively treated
patients with the diagnosis of Graves’ disease were reviewed.
Datacollectedincludedtheage,height,weight,ethnicity,and
gender.Medicationanddoseinformationwerealsocollected.
Medical records were reviewed to determine if adverse events
occurred,andthelengthoftimefrominitiating therapyuntil
when adverse events developed. For those patients receiving
treatment with either surgery or radioactive iodine, this
was noted. Initial thyroid function tests at diagnosis along




are presented as mean±SEM. Statistical analysis among
groups was performed by the Student’s t-test.
3. Results
One hundred consecutively treated patients evaluated for
Graves’ disease were evaluated. The range in the patient age
was from 3.5 years to 18 years. The mean age was 13.2±3.5
years. 72% of the patients were female; 28% of the patients
were male. 70% of patients were from the New Haven CT
area; 30% of patients were from outside of the New Haven
area. 62% of the individuals were Caucasian, 16% were
Hispanic, 16% were Asian, and 6% were African American.
At diagnosis, TSH levels were 0.01±0mU/L. The initial
t o t a lT 4l e v e l sw e r e1 8 . 3 ±2.0mcg/dL. The initial free
T4 levels were 4.9±2.4ng/dL. Initial total T3 levels were
530±175ng/dL. TSI levels were available in 73% of the
individuals and were 180±70%. In all the patients in whom
TSI was measured, levels were elevated.
The patients were treated with average daily dose of MMI
of 0.3±0.2mg/kg/day. Medication was given once a day in
60% of patients and twice daily in 40% of patients.
A d v e r s ee v e n t sa t t r i b u t e dt ot h eu s eo fM M I ,w e r es e e n
in 19 patients (Table 1) .T h em o s tc o m m o ns i d ee ﬀects
included pruritus and hives, which were seen in eight
patients. Five patients developed diﬀuse arthralgia, muscle
pain, and/or joint pain. One patient developed lymphopenia
and esoinophilia. Two patients developed neutropenia with
absolute neutrophil counts of 500 and 750 counts per cubic
ml. This problem was detected upon evaluation of new onset
fever. Three patients developed Stevens-Johnson syndrome
with diﬀuse cutaneous eruption and mucous membrane
involvement. One patient with Stevens-Johnson syndrome
required hospitalization for three days. Mild liver injuryliver
injury was observed in one patient. In this individual,
the aspartate aminotransferase (AST; SGOT) was 184u/L,
the alanine aminotransferase (ALT; SGPT) was 379u/L,
the alkaline phosphatase was 355u/L; the bilirubin was
0.18mg/dL;andthegamma-glutamyltranspeptidase,(GGT)
was 193u/L. The age, methimazole dose, and length of timeInternational Journal of Pediatric Endocrinology 3
from initiation of treatment until development of adverse
events for each patient are shown in Table 1.
When clinical characteristics were compared in individu-
als who developed adverse events to methimazole with those
who did not develop such reactions, no diﬀerences were
detected as related to age, gender, dose, or ethnicity. There
was no relationship to initial thyroid hormone levels, or
circulating levels of immunoglobulins.
Of those individuals who developed adverse events to
MMI, thyroidectomy was performed in three patients (ages
3–4 years). Radioactive iodine was administered to thirteen
individuals (age range 8–18 years), and three patients were
changed to PTU, as treatment with radioactive iodine or
surgery was refused by the families.
Adverse events to MMI occurred within one month of
therapy in 20% of the patients, within three months of
therapy in 50% of patients, and within six months of therapy
in 90% of patients. In three patients, adverse events occurred
after one and a half years of treatment.
4. Discussion
Published reports related to the treatment of children with
Graves’ disease have generally involved cohorts of children
treated with PTU [6–14]. These studies reveal an incidence
of minor adverse events between 1% [13] and 15% [12].
Within reports in which the use of MMI has been described,
there has been little description of adverse events associated
with this medication. Our data suggest that methimazole can
be associated with a risk of adverse events in up to 19% of
individuals. If one excludes the eight patients with pruritus
and hives, which are minor side eﬀects, the more serious
adverse events were found in 11% of patients.
Based on published reports describing outcomes for
children treated with antithyroid medications for Graves’
disease, up to 10 years ago, PTU was more widely used
than MMI [11–13]. More recent data however, suggest that
two thirds of children in the United States treated with
antithyroid medications are now being treated with MMI,
and one-third are treated with PTU [4].
Recently, a concerning risk of hepatotoxicity resulting in
liver failure in children and adults and in pregnant women
treated with PTU has been brought to attention [4, 16].
Based on the incidence of reported cases of acute liver
failure and liver transplantation associated with PTU, it is
estimated that up to 1 in 2,000 children will sustain acute
liver injury in response to PTU [4, 16]. As the result, it is
recommended that PTU not be used in children except in
special circumstances, such as when an individual has had a
toxic reaction to methimazole, and antithyroid medication
is needed until deﬁnitive treatment either in the form of
surgery or radioactive iodine can be performed [4]. As such,
MMI use in the pediatric population is expected to increase.
Our data show that MMI is associated with adverse
events in children. The most common adverse events were
related to cutaneous eruptions and arthralgia. We observed
one child who had cholestatic liver injury associated with
methimazole.Intheadultpopulation, cholestaticliverinjury
has been reported to be associated with MMI use [17]. MMI
associated liver injury is most typically seen in individuals
who are older rather than younger, and in those who are
treated with higher rather than lower MMI doses [17]. There
were no reported cases of severe liver injury in any of our
patients. In the individual who developed modest transam-
inase and alkaline phosphatase elevations, this condition
reversed fully within one month after discontinuation of the
medication.
Of concern was the development of Stevens-Johnson
syndrome in three of the children, one of which required
hospitalization. Ineachchild,thecondition reversedwithout
long-term sequelae. Of note, the three patients who devel-
oped Stevens-Johnson syndrome were receiving large doses
of MMI (30mg). At present we do not know, though, if the
risk of Stevens-Johnson syndrome is dose-related. Whereas
most of the adverse events associated with MMI occurred
within the ﬁrst half year of the treatment onset, we observed
adverse events after one and a half years of therapy in
threechildren.Theseobservationsshowthatchildrentreated
with MMI warrant close follow-up for the development of
potential toxic events.
Our observations raise the question about the utility of
routine monitoring of hematological proﬁles or liver func-
tion tests or transaminase levels in patients on antithyroid
medications. At present there is little evidence to support
the notion that routine monitoring of these parameters
is eﬀective in minimizing the risk of antithyroid drug
related adverse events [3, 18, 19]. If PTU is used, it is
recommended that PTU should be stopped immediately and
liver function and hepatocellular integrity be assessed in
children who experience anorexia, pruritis rash, jaundice,
light colored stool or dark urine, joint pain, right upper
quadrant pain or abdominal bloating, nausea or fatigue
[19, 20]. In addition, PTU and MMI should be stopped
immediatelyandwhitebloodcountsbemeasuredinchildren
who develop fever, mouth sores, pharyngitis, or feel ill [3].
While routine monitoring of white blood counts may detect
early agranulocytosis, it is not recommended because of the
rarity of the condition and the lack of cost-eﬀectiveness
[3, 18]. Agranulocytosis has been reported in about 0.3% of
adult patients taking MMI or PTU [3, 18, 19]. Data of the
incidence of agranulocytosis in children is not available, but
isestimatedtobeverylow.Inadults,agranulocytosisisdose-
dependent with MMI, and rarely occurs at low doses [3, 18].
Whenitdevelops,agranulocytosistypicallyoccurswithinthe
ﬁrst 100 days of therapy in 95% of individuals [3, 18].
We recognized that a potential limitation of our study is
that our referral patterns may bias our outcomes, as some
of the patients coming for second opinions may have been
treated beforehand with MMI doses higher than we typically
use. The demographics of self-referred patients may also
diﬀer from that seen in a typical cross-section of children
with Graves’ disease. Our patients are also not typically
treated beyond two years with MMI, which inﬂuences our
ability to observe long-term side eﬀects.
At present, PTU and MMI are the only antithyroid drugs
availableforGraves’diseaseintheUnitedStates[3].PTUwas
introduced for clinical use in 1948 and MMI in 1950 [20].
Although MMI is less hepatotoxic than PTU, our data show4 International Journal of Pediatric Endocrinology
that MMI use is indeed associated with potential adverse
events, which can be serious. Considering the hepatotoxicity
risk associated with PTU, and the other minor and major
adverse events associated with both PTU and MMI, strong
consideration should be given to the development of less
toxic antithyroid medications for use in children and adults.
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